Neoadjuvant ipilimumab-nivolumab combination induces major pathological response in mismatch repair-deficient colon cancer

MUNICH — Neoadjuvant treatment with nivolumab and ipilimumab induced major pathologic response in 100% of patients with early-stage, mismatch repair-deficient colon cancers, according to results of the phase 2 NICHE trial presented at European Society for Medical Oncology Congress.
Immune checkpoint inhibition has become a standard treatment approach for many cancer types.
These agents are of particular interest in mismatch repair-deficient tumors because they have high mutational load and upregulation of immune checkpoints, according to Myriam Chalabi, MD, PhD, oncologist in the

Source link

Related posts

‘Super donors’ may be pivotal to the future of fecal transplants


Diet-as-therapy in IBD relies on shared decision-making, compliance


Older donor livers still discarded despite improving mortality outcomes


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy